Azadeh Meshkini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Azadeh Meshkini has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Razieh Yazdanparast
6 shared publicationsElnaz Sistanipour
Ferdowsi Univ Mashhad, Fac Sci, Dept Chem, Mashhad 9177948974, Iran
4 shared publicationsMaryam M. Matin
Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
3 shared publications- Razieh Yazdanparast
University of Tehran
3 shared publications Azadeh Izadi
Biochemical Research Center, Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
2 shared publications- Elaheh K. Goharshadi
Ferdowsi University of Mashhad
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 43
Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches
Background: Integrated bioinformatics approaches were used to identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer (TNBC). Methods: Microarray (164 early-stage, 33 advanced-stage, and 53 normal samples) and RNA-seq (113 normal, 163 early-stage, and 30 advanced-stage TNBC samples) datasets were analyzed. Differentially expressed genes (DEGs) were identified, followed by co-expression analysis using Weighted Gene Co-expression Network Analysis (WGCNA) and protein–protein interaction analysis using the STRING database. miRNA co-regulation was evaluated using multiMiR and TCGA correlation analyses. Candidate genes were validated using UALCAN and immunohistochemistry data. Molecular docking assessed potential therapeutic agents. Results: Novel stage-specific candidate biomarkers were identified, including DNAJC6 , SKP2 , MOCOS , and NCAPD2 in early-stage TNBC, and F11R , FOXO6 , PPP4C , and TMEM51 in advanced-stage TNBC. UALCAN analysis confirmed the dysregulation of these genes across 23 additional malignancies. STRING-based network analysis revealed stage-specific protein–protein interactions, including SKP2–SKP1 in early-stage and F11R–TJP1 in advanced-stage TNBC. miRNA co-regulation distinguished early-stage TNBC through PI3K–AKT–related pathways and advanced-stage TNBC through tumor progression–associated pathways. Docking-based drug repurposing highlighted conventional agents (e.g., doxorubicin) and potential novel candidates (e.g., sunitinib). Conclusion: This study identifies novel stage-specific gene candidates and suggests repurposable drugs for TNBC, supporting progression-specific targeted therapeutic strategies.
- 28 May 2026
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 43
Open AccessStage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches
Background: Integrated bioinformatics approaches were used to identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer (TNBC). Methods: Microarray (164 early-stage, 33 advanced-stage, and 53 normal samples) and RNA-seq (113 normal, 163 early-stage, and 30 advanced-stage TNBC samples) datasets were analyzed. Differentially expressed genes (DEGs) were identified, followed by co-expression analysis using Weighted Gene Co-expression Network Analysis (WGCNA) and protein–protein interaction analysis using the STRING database. miRNA co-regulation was evaluated using multiMiR and TCGA correlation analyses. Candidate genes were validated using UALCAN and immunohistochemistry data. Molecular docking assessed potential therapeutic agents. Results: Novel stage-specific candidate biomarkers were identified, including DNAJC6 , SKP2 , MOCOS , and NCAPD2 in early-stage TNBC, and F11R , FOXO6 , PPP4C , and TMEM51 in advanced-stage TNBC. UALCAN analysis confirmed the dysregulation of these genes across 23 additional malignancies. STRING-based network analysis revealed stage-specific protein–protein interactions, including SKP2–SKP1 in early-stage and F11R–TJP1 in advanced-stage TNBC. miRNA co-regulation distinguished early-stage TNBC through PI3K–AKT–related pathways and advanced-stage TNBC through tumor progression–associated pathways. Docking-based drug repurposing highlighted conventional agents (e.g., doxorubicin) and potential novel candidates (e.g., sunitinib). Conclusion: This study identifies novel stage-specific gene candidates and suggests repurposable drugs for TNBC, supporting progression-specific targeted therapeutic strategies.
- 12 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 304 (Pt 2) , 140983
Transformative nanoantioxidant chitosan films: High-performance active packaging with minimal cytotoxicity
- 12 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 304 (Pt 2) , 140983
Transformative nanoantioxidant chitosan films: High-performance active packaging with minimal cytotoxicity
- 30 April 2023
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 226, 113333
Tumor tropic delivery of FU.FA@NSs using mesenchymal stem cells for synergistic chemo-photodynamic therapy of colorectal cancer
- 30 April 2023
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 226, 113333
Tumor tropic delivery of FU.FA@NSs using mesenchymal stem cells for synergistic chemo-photodynamic therapy of colorectal cancer
- Open Access
- 21 April 2023
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 14 (1) , 1-27
g-C3N4-based photoresponsive magnetic nanocatalyst drives type-I photodynamic therapy under visible light irradiation, boosting chemo/chemodynamic synergistic therapy of colon cancer
Background: Fenton reaction-based chemodynamic therapy (CDT) is regarded as a highly tumor-specific treatment modality due to its intrinsic tumor microenvironment (TME)-specific targeting properties, such as high amounts of lactic acid and H2O2. To improve the therapeutic efficacy of CDT, in this study, a self-tracking and external stimuli-responsive Fenton nanoreactor was accompanied by type I photodynamic therapy. Results: A cisplatin-containing H2O2 self-supplying heterogeneous Fenton nanocatalyst (CaO2.CDDP@Fe3O4) was constructed, and it was accompanied by graphitic carbon nitride (g-C3N4) nanosheets as a photosensitizer. The hybrid nanocomposite was decorated with ascorbic acid, which improved the tumor-targeting capabilities of the final construct (CCFCA). Besides the generation of hydroxyl radicals (·OH) by metal-based Fenton nanocatalyst (CaO2.CDDP@Fe3O4), g-C3N4-driven nonmetal-based Fenton reaction translated external energy into extremely lethal free radicals within the tumor cells through oxygen-independent type-I PDT. According to 2D and 3D cell culture experiments, CCFCA demonstrated cancer cell selectivity and a high cellular uptake efficiency under a static magnetic field (SMF) and visible light irradiation. Further investigations showed that CCFCA suppressed the antioxidant system and altered the mitochondrial membrane potential and consequently caspase activity, causing apoptosis in cancer cells. The enhanced tumor-inhibitory capability of the nanocomposites was shown by the increased anti-tumor activity of CCFCA in treated mice under SMF and light irradiation as compared to those treated with the free drug. Moreover, no deleterious effects on normal tissues and blood cells were observed in CCFCA-treated mice. Conclusion: Based on the results obtained, dual Fenton reactions were provided in a simple platform (CCFCA) where the cooperative combination of multiple approaches (chemotherapy, magnetic therapy, and PDT) enhanced CDT efficiency against colon cancer.
- 21 April 2023
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 14 (1) , 1-27
Open Accessg-C3N4-based photoresponsive magnetic nanocatalyst drives type-I photodynamic therapy under visible light irradiation, boosting chemo/chemodynamic synergistic therapy of colon cancer
Background: Fenton reaction-based chemodynamic therapy (CDT) is regarded as a highly tumor-specific treatment modality due to its intrinsic tumor microenvironment (TME)-specific targeting properties, such as high amounts of lactic acid and H2O2. To improve the therapeutic efficacy of CDT, in this study, a self-tracking and external stimuli-responsive Fenton nanoreactor was accompanied by type I photodynamic therapy. Results: A cisplatin-containing H2O2 self-supplying heterogeneous Fenton nanocatalyst (CaO2.CDDP@Fe3O4) was constructed, and it was accompanied by graphitic carbon nitride (g-C3N4) nanosheets as a photosensitizer. The hybrid nanocomposite was decorated with ascorbic acid, which improved the tumor-targeting capabilities of the final construct (CCFCA). Besides the generation of hydroxyl radicals (·OH) by metal-based Fenton nanocatalyst (CaO2.CDDP@Fe3O4), g-C3N4-driven nonmetal-based Fenton reaction translated external energy into extremely lethal free radicals within the tumor cells through oxygen-independent type-I PDT. According to 2D and 3D cell culture experiments, CCFCA demonstrated cancer cell selectivity and a high cellular uptake efficiency under a static magnetic field (SMF) and visible light irradiation. Further investigations showed that CCFCA suppressed the antioxidant system and altered the mitochondrial membrane potential and consequently caspase activity, causing apoptosis in cancer cells. The enhanced tumor-inhibitory capability of the nanocomposites was shown by the increased anti-tumor activity of CCFCA in treated mice under SMF and light irradiation as compared to those treated with the free drug. Moreover, no deleterious effects on normal tissues and blood cells were observed in CCFCA-treated mice. Conclusion: Based on the results obtained, dual Fenton reactions were provided in a simple platform (CCFCA) where the cooperative combination of multiple approaches (chemotherapy, magnetic therapy, and PDT) enhanced CDT efficiency against colon cancer.
- Open Access
- 1 December 2021
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 167, 106031
Tailoring the proliferation of fibroblast cells by multiresponsive and thermosensitive stem cells composite F127 hydrogel containing folic acid.MgO:ZnO/chitosan hybrid microparticles for skin regeneration
- 1 December 2021
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 167, 106031
Open AccessTailoring the proliferation of fibroblast cells by multiresponsive and thermosensitive stem cells composite F127 hydrogel containing folic acid.MgO:ZnO/chitosan hybrid microparticles for skin regeneration
- 1 August 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 127, 112238
Fenton-magnetic based therapy by dual-chemodrug-loaded magnetic hydroxyapatite against colon cancer
- 1 August 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 127, 112238
Fenton-magnetic based therapy by dual-chemodrug-loaded magnetic hydroxyapatite against colon cancer